The mortality was not impacted by underlying MPN diagnosis; like a subgroup analysis of the FPCCVT cohort that found there was no significant difference in the mortality observed in the JAK2V617F‐positive cohort versus those without JAK2 mutation (n = 216, including nine patients with JAK2 mutation) [10]. This evidence concerns the gene JAK2 and myeloproliferative neoplasm.